Jumonji AT-rich Interactive Domain 1B Overexpression is Associated with the Development and Progression of Glioma

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2016 Jun 2

PMID 27246838

Citations 7

Authors

Liping Fang

Jiuhan Zhao

Dan Wang

Liyu Zhu

Jian Wang

Kui Jiang

Affiliations

Soon will be listed here.

Abstract

Previous studies have suggested that jumonji AT-rich interactive domain 1B (JARID1B) plays an important role in the genesis of some types of cancer, and it is therefore considered to be an important drug target protein. Although the expression of JARID1B has been researched in some types of cancer, little is known about JARID1B expression in glioma and its function in the tumorigenesis of gliomas. In the present study, we examined the expression of JARID1B in glioma. In addition, RT-PCR, western blot analysis and immunohistochemical analysis were performed using glioma tissue samples and the results revealed that JARID1B expression increased according to the histological grade of glioma. However, in the normal brain tissue samples JARID1B expression was barely detected. Kaplan‑Meier analysis revealed that higher JARID1B expression in patients with glioma was associated with a poorer prognosis. The overexpression of JARID1B stimulated the proliferation and migration of glioma cells as well as sphere formation, whereas suppressing the expression of JARID1B produced opposite effects. The overexpression of JARID1B increased the tumorigenicity of glioma cells in vivo in a nude mouse xenograft model of glioma. Moreover, the activation of phosphorylated (p-)Smad2 contributes to JARID1B-induced oncogenic activities. These findings suggest that JARID1B is involved in the pathogenesis of glioma, and that the downregulation of JARID1B in glioma cells may be a therapeutic target for the treatment of patients with glioma.

Citing Articles

KDM5B predicts temozolomide-resistant subclones in glioblastoma.

Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull H, Cima I iScience. 2024; 27(1):108596.

PMID: 38174322 PMC: 10762356. DOI: 10.1016/j.isci.2023.108596.

KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.

Zhang S, Cao J, Yan Q Adv Exp Med Biol. 2023; 1433:113-137.

PMID: 37751138 DOI: 10.1007/978-3-031-38176-8_6.

Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?.

Ohguchi Y, Ohguchi H Cancers (Basel). 2022; 14(13).

PMID: 35805040 PMC: 9265395. DOI: 10.3390/cancers14133270.

Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.

Tortelli T, Tamura R, de Souza Junqueira M, da Silva Mororo J, Bustos S, Natalino R Aging (Albany NY). 2021; 13(18):21914-21940.

PMID: 34528900 PMC: 8507253. DOI: 10.18632/aging.203528.

KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.

Gaillard S, Charasson V, Ribeyre C, Salifou K, Pillaire M, Hoffmann J Biol Open. 2021; 10(5).

PMID: 34184733 PMC: 8181900. DOI: 10.1242/bio.057729.

References

Seward D, Cubberley G, Kim S, Schonewald M, Zhang L, Tripet B . Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1 JmjC proteins. Nat Struct Mol Biol. 2007; 14(3):240-2. DOI: 10.1038/nsmb1200. View

Kano Y, Konno M, Ohta K, Haraguchi N, Nishikawa S, Kagawa Y . Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth. Mol Clin Oncol. 2014; 1(4):753-757. PMC: 3915624. DOI: 10.3892/mco.2013.127. View

Mitra D, Das P, Huynh F, Jones F . Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem. 2011; 286(47):40531-5. PMC: 3220509. DOI: 10.1074/jbc.M111.304865. View

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann K, Speicher D . Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013; 23(6):811-25. PMC: 3810180. DOI: 10.1016/j.ccr.2013.05.003. View

Kim H, Haraguchi N, Ishii H, Ohkuma M, Okano M, Mimori K . Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol. 2011; 19 Suppl 3:S539-48. DOI: 10.1245/s10434-011-2040-5. View

Wang Q, Wang Y, Zhang Y, Zhang Y, Xiao W . Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells. Lab Invest. 2015; 95(5):469-79. DOI: 10.1038/labinvest.2015.33. View

Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D . Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011; 71(21):6899-908. DOI: 10.1158/0008-5472.CAN-11-1523. View

Wang Y, Zhang P, Liu Z, Wang Q, Wen M, Wang Y . CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR. Mol Cancer. 2014; 13:252. PMC: 4246448. DOI: 10.1186/1476-4598-13-252. View

Wynder C, Stalker L, Doughty M . Role of H3K4 demethylases in complex neurodevelopmental diseases. Epigenomics. 2011; 2(3):407-18. DOI: 10.2217/epi.10.12. View

10.

Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P . CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2013; 74(2):520-31. PMC: 3934357. DOI: 10.1158/0008-5472.CAN-13-2182. View

11.

Opocher E, Kremer L, Da Dalt L, van de Wetering M, Viscardi E, Caron H . Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer. 2006; 42(12):1807-16. DOI: 10.1016/j.ejca.2006.02.022. View

12.

Yamamoto S, Wu Z, Russnes H, Takagi S, Peluffo G, Vaske C . JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014; 25(6):762-77. PMC: 4079039. DOI: 10.1016/j.ccr.2014.04.024. View

13.

Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G . Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer. 2014; 13:137. PMC: 4057898. DOI: 10.1186/1476-4598-13-137. View

14.

Grzmil M, Morin Jr P, Lino M, Merlo A, Frank S, Wang Y . MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. Cancer Res. 2011; 71(6):2392-402. DOI: 10.1158/0008-5472.CAN-10-3112. View

15.

Albert M, Schmitz S, Kooistra S, Malatesta M, Torres C, Rekling J . The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3. PLoS Genet. 2013; 9(4):e1003461. PMC: 3630093. DOI: 10.1371/journal.pgen.1003461. View

16.

DeSantis C, Lin C, Mariotto A, Siegel R, Stein K, Kramer J . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-71. DOI: 10.3322/caac.21235. View

17.

Chen R, Ravindra V, Cohen A, Jensen R, Salzman K, Prescot A . Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 2015; 38(3):E2. DOI: 10.3171/2015.1.FOCUS14745. View

18.

Parvani J, Taylor M, Schiemann W . Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia. 2011; 16(2):127-46. PMC: 3723114. DOI: 10.1007/s10911-011-9207-3. View

19.

Wendt M, Allington T, Schiemann W . Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009; 5(8):1145-68. PMC: 2858056. DOI: 10.2217/fon.09.90. View

20.

Catchpole S, Spencer-Dene B, Hall D, Santangelo S, Rosewell I, Guenatri M . PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol. 2011; 38(5):1267-77. DOI: 10.3892/ijo.2011.956. View